United States of America based
A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development.
TechnologiesAI Companies (Drug Discovery)
The SCULPT™ process builds and evaluates small molecule libraries that consist of thousands to millions of members. Iterations are performed until candidates with optimal properties and matches to target features are obtained.
Our focus areas are unmet needs in oncology, drug-resistant bacterial infections, and other life-threatening diseases. The SCULPT platform enables a new way to approach these problems, opening the door for the development of novel medicines.
A2A oncology programs apply our therapeutic design methodology towards inhibiting protein-protein interactions (PPIs). Pharmacological targets of this class have important roles in a range of cancer types, but have been traditionally challenging to inhibit. SCULPT enables the design of novel ligands specifically to match the unique topological features of this target class.
Targets for A2A antibiotic programs were selected based on their broad-spectrum applicability to gram-negative bacterial species, as well as novelty to circumvent rapid target-associated resistance. A unique bioinformatics approach was incorporated into the SCULPT process to yield candidates with "antibiotic-like" properties, in order to maximize the chances of activity and minimize drug efflux.
No services posted yet